Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Ropivacaine hydrochloride
Drug ID BADD_D01968
Description Ropivacaine is an aminoamide local anaesthetic drug commonly marketed by AstraZeneca under the trade name Naropin. It is present as a racemic mixture of the enantiomers containing equal proportions of the “S” and “R” forms. The marketed form contains the single S-enantiomer as the active ingredient.
Indications and Usage Used in obstetric anesthesia and regional anesthesia for surgery.
Marketing Status approved
ATC Code N01BB09
DrugBank ID DB00296
KEGG ID D04048
MeSH ID D000077212
PubChem ID 175804
TTD Drug ID D09RHQ
NDC Product Code 25021-671; 55150-197; 68083-263; 0409-9300; 70121-1734; 51552-1590; 0143-9263; 52584-286; 55150-201; 63323-286; 63323-288; 70069-063; 70121-1733; 70121-1735; 61876-0071; 43066-027; 0404-9924; 70069-067; 55150-196; 63323-285; 0409-9302; 70069-061; 70121-1732; 72572-707; 55150-200; 65145-107; 65145-108; 0409-9301; 70069-062; 76339-124; 17478-082; 43066-023; 0143-9266; 48954-722; 25021-652; 68083-262; 46014-1058; 49452-6303; 65372-1159; 17478-081; 0409-9303; 70069-064; 49386-025; 43066-015; 43066-019; 55150-198; 63323-287; 65145-109; 65145-110; 70069-065; 70069-066; 0143-9264; 0143-9265; 55150-195; 55150-199
UNII V910P86109
Synonyms Ropivacaine | 1-Propyl-2',6'-pipecoloxylidide | 1 Propyl 2',6' pipecoloxylidide | Naropin | Ropivacaine Monohydrochloride | Ropivacaine Hydrochloride | AL 381 | AL-381 | AL381 | Naropeine | LEA 103 | LEA-103 | LEA103 | Ropivacaine Monohydrochloride, (S)-isomer
Chemical Information
Molecular Formula C17H27ClN2O
CAS Registry Number 98717-15-8
SMILES CCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Ventricular arrhythmia02.03.04.006--
Ventricular fibrillation02.03.04.008--
Ventricular tachycardia02.03.04.010--
Vertigo04.04.01.003; 17.02.12.002--
Vision blurred06.02.06.007; 17.17.01.010--
Visual impairment06.02.10.013---
Vomiting07.01.07.003--
Foetal acidosis18.03.02.002---
Deep vein thrombosis24.01.02.003---
Acute coronary syndrome02.02.02.015; 24.04.04.011---
Musculoskeletal discomfort15.03.04.001---
Affect lability19.04.01.001---
Rectal tenesmus07.03.03.001; 15.05.03.011---
Neonatal tachypnoea18.04.09.003; 22.11.01.003---
Post procedural complication12.02.05.018---
Metabolic disorder14.11.01.001---
Muscle relaxant therapy25.16.01.001---
Blood alkaline phosphatase increased13.04.02.004--
Neurological symptom17.02.05.010---
Breast disorder21.05.04.004---
Cardiac disorder02.11.01.003---
Mental disorder19.07.01.002---
Neonatal infection11.01.08.032; 18.04.12.001---
Central nervous system stimulation25.04.01.001---
Respiratory disorder neonatal18.04.09.002; 22.11.01.002---
Ill-defined disorder08.01.03.049---
Extradural abscess11.01.03.006; 17.06.07.003---
Neonatal complications of substance abuse12.03.01.050; 18.04.13.002; 19.07.06.016---
Cranial nerve paralysis17.04.01.002---
Pulmonary function test decreased13.19.01.001---
The 7th Page    First    Pre   7 8    Next   Last    Total 8 Pages